Manuscripts and Publications

Filters: Author is Kanner, Richard E  [Clear All Filters]
2021
Radicioni G, Ceppe A, Ford AA, Alexis NE, R Barr G, Bleecker ER, Christenson SA, Cooper CB, Han MK, Hansel NN et al..  2021.  Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 9(11):1241-1254.
Ejike CO, Woo H, Galiatsatos P, Paulin LM, Krishnan JA, Cooper CB, Couper DJ, Kanner RE, Bowler RP, Hoffman EA et al..  2021.  Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes.. Am J Respir Crit Care Med. 203(8):987-997.
Oh AL, Mularski RA, Barjaktarevic I, R Barr G, Bowler RP, Comellas AP, Cooper CB, Criner GJ, Han MK, Hansel NN et al..  2021.  Defining Resilience to Smoking-related Lung Disease: A Modified Delphi Approach from SPIROMICS.. Ann Am Thorac Soc. 18(11):1822-1831.
Li F, Choi J, Zou C, Newell JD, Comellas AP, Lee CHyun, Ko H, R Barr G, Bleecker ER, Cooper CB et al..  2021.  Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images.. Sci Rep. 11(1):4916.
Zusman M, Gassett AJ, Kirwa K, R Barr G, Cooper CB, Han MK, Kanner RE, Koehler K, Ortega VE, Rd RPaine et al..  2021.  Modeling residential indoor concentrations of PM , NO , NO , and secondhand smoke in the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) Air study.. Indoor Air. 31(3):702-716.
Fortis S, Comellas AP, Bhatt SP, Hoffman EA, Han MK, Bhakta NR, Paine R, Ronish B, Kanner RE, Dransfield M et al..  2021.  Ratio of FEV/Slow Vital Capacity of < 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function.. Chest. 160(1):94-103.
2020
Paulin LM, Gassett AJ, Alexis NE, Kirwa K, Kanner RE, Peters S, Krishnan JA, Paine R, Dransfield M, Woodruff PG et al..  2020.  Association of Long-term Ambient Ozone Exposure With Respiratory Morbidity in Smokers.. JAMA Intern Med. 180(1):106-115.
Stott-Miller M, Müllerová H, Miller B, Tabberer M, Baou CEl, Keeley T, Martinez FJ, Han ML, Dransfield M, Hansel NN et al..  2020.  Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort.. Int J Chron Obstruct Pulmon Dis. 15:2467-2476.
Ortega VE, Li X, O'Neal WK, Lackey L, Ampleford E, Hawkins GA, Grayeski PJ, Laederach A, Barjaktarevic I, R Barr G et al..  2020.  The Effects of Rare Variants on Lung Function and Emphysema in SPIROMICS.. Am J Respir Crit Care Med. 201(5):540-554.
Cooper CB, Paine R, Curtis JL, Kanner RE, Martinez CH, Meldrum CA, Bowler R, O'Neal W, Hoffman EA, Couper D et al..  2020.  Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort.. Int J Chron Obstruct Pulmon Dis. 15:1887-1898.
Burkes RM, Ceppe AS, Couper DJ, Comellas AP, J Wells M, Peters SP, Criner GJ, Kanner RE, Paine R, Christenson SA et al..  2020.  Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.. Chronic Obstr Pulm Dis. 7(4):370-381.
Strand M, Austin E, Moll M, Pratte KA, Regan EA, Hayden LP, Bhatt SP, Boriek AM, Casaburi R, Silverman EK et al..  2020.  A Risk Prediction Model for Mortality Among Smokers in the COPDGene® Study.. Chronic Obstr Pulm Dis. 7(4):346-361.
2018
Fawzy A, Putcha N, Paulin LM, Aaron CP, Labaki WW, Han MK, Wise RA, Kanner RE, Bowler RP, R Barr G et al..  2018.  Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts.. Respir Res. 19(1):20.
Li X, Ortega VE, Ampleford EJ, R Barr G, Christenson SA, Cooper CB, Couper D, Dransfield MT, Han MLan K, Hansel NN et al..  2018.  Genome-wide association study of lung function and clinical implication in heavy smokers.. BMC Med Genet. 19(1):134.
Pirozzi CS, Gu T, Quibrera PM, Carretta EE, Han MK, Murray S, Cooper CB, Tashkin DP, Kleerup EC, Barjaktarevic I et al..  2018.  Heterogeneous burden of lung disease in smokers with borderline airflow obstruction.. Respir Res. 19(1):223.
Smith BM, Traboulsi H, Austin JHM, Manichaikul A, Hoffman EA, Bleecker ER, Cardoso WV, Cooper C, Couper DJ, Dashnaw SM et al..  2018.  Human airway branch variation and chronic obstructive pulmonary disease.. Proc Natl Acad Sci U S A. 115(5):E974-E981.
Haghighi B, Choi S, Choi J, Hoffman EA, Comellas AP, Newell JD, R Barr G, Bleecker E, Cooper CB, Couper D et al..  2018.  Imaging-based clusters in current smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS).. Respir Res. 19(1):178.
Putcha N, Paul GG, Azar A, Wise RA, O'Neal WK, Dransfield MT, Woodruff PG, Curtis JL, Comellas AP, M Drummond B et al..  2018.  Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS.. PLoS One. 13(4):e0194924.
Labaki WW, Xia M, Murray S, Curtis JL, R Barr G, Bhatt SP, Bleecker ER, Hansel NN, Cooper CB, Dransfield MT et al..  2018.  NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.. Respir Med. 140:87-93.
Paulin LM, Smith BM, Koch A, Han ML, Hoffman EA, Martinez C, Ejike C, Blanc PD, Rous J, R Barr G et al..  2018.  Occupational Exposures and Computed Tomographic Imaging Characteristics in the SPIROMICS Cohort.. Ann Am Thorac Soc. 15(12):1411-1419.

Pages